Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJALL23H: Combination Antigen-Directed Induction Therapy for Newly Diagnosed B-Cell Precursor ALL and Lymphoma
NCT06533748Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jan 2025
- Primary completion
- May 2028
- Modality
- scFv Fragments, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin, blinatumomab in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by St. Jude Children's Research Hospital. Started Jan 2025; status: recruiting.
02
Drugs
inotuzumab ozogamicinblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT06533748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533748.